Evidence map›Paper›PMID 31267251›Full record

ReviewCurrent allergy and asthma reports2019

Laser Light Therapy in Inflammatory, Musculoskeletal, and Autoimmune Disease.

Victoria A Wickenheisser, Emilia Marta Zywot, Emily Mary Rabjohns, Hyun Ho Lee, David S Lawrence, Teresa Kathleen Tarrant

Registry-linked trialAbstract readReview
In one paragraph

Review in Current allergy and asthma reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07380230 (Efficacy and Safety of Qibei Jiedu Formula Versus Placebo in Preventing and Managing Acute Radiation Dermatitis in Breast Cancer Patients), which is not on this map. Cited by 48 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07380230 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy and Safety of Qibei Jiedu Formula Versus Placebo in Preventing and Managing Acute Radiation Dermatitis in Breast Cancer Patients: A Prospective, Double-blind, Randomized Controlled Trial

TypeinterventionalSponsorLI FENGRan2026 to 2026Enrolled60ConditionsAcute Radiation Dermatitis, Traditional Chinese Medicine (TCM), Breast CancerArmsStandard Basic Treatment Combined with Qibei Jiedu Formula, Standard Basic Treatment Combined with Qibei Jiedu Formula simulator
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Treatments in oral lichen planus: a review.Frontiers in oral health · 2026
    Review
  16. Article
  17. Article
  18. Aesthetic Treatment Considerations in Patients with Cutaneous Autoimmune Disease.The Journal of clinical and aesthetic dermatology · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Victoria A WickenheisserDuke School of Medicine, Durham, NC, USA.
Emilia Marta ZywotDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, USA.
Emily Mary RabjohnsDuke Department of Medicine, Division of Rheumatology and Immunology, DUMC 3874, 200 Trent Dr., Durham, NC, 27710, USA.
Hyun Ho LeeDuke Department of Medicine, Division of Rheumatology and Immunology, DUMC 3874, 200 Trent Dr., Durham, NC, 27710, USA.
David S LawrenceDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, USA.
Teresa Kathleen TarrantDuke School of Medicine, Durham, NC, USA. teresa.tarrant@duke.edu.

Funding

CANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0M
NCI NIH HHS T32 CA071341
6 · The paper itself

Abstract

purpose of reviewThe goal of this review is to summarize the field to date and to discuss strengths and limitations of low-level laser (light) therapy (LLLT) for the future investigation as a treatment of inflammatory disease. RECENT

findingsLLLT is a promising therapeutic, particularly for those diseases of skin and joints because they are most accessible to treatment. Indeed, the known mechanisms of LLLT support its use for anti-inflammatory purposes, as well as stimulation of tissue growth and repair. Although the standard of care for the majority of inflammatory diseases is immunosuppressive agents such as corticosteroids with undesirable toxicities, LLLT offers a unique approach by being non-invasive and incurring minimal side effects. It is also relatively inexpensive and accessible and even has the possibility to be patient directed at home. There is evidence that LLLT is able to modulate the immune system at the skin and joint, and it has been shown to be efficacious in humans by affecting bacterial colonization as it may pertain to chronic rhinosinusitis. However, there is variability in the methods of laser application as well as a lack of evidence for laser type, dose-ranging studies, and wavelength selection that create barriers to the implementation of LLLT without further more rigorous and standardized study. The heterogeneity makes it difficult to draw strong conclusions about the efficacy of LLLT and its mechanisms.

Indexed as

AnimalsAutoimmune DiseasesHumansInflammationLaser TherapyLow-Level Light TherapyMusculoskeletal DiseasesAutoimmunityInflammatory diseaseLow-level light/laserPhotodynamic therapyPhototherapeuticsPhototherapy

Identifiers

PMID31267251
PMCPMC7357616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.